Localização do estoque

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Estoque sujeito a disponibilidade

Documentation

Baixar MSDS

Baixar COA de amostra

Inclui: HPLC, MASS/LC-MS, RMN de 1H, FT-IR, teor, Relatório de Elucidação Estrutural (SER) e dados analíticos adicionais dependendo do produto.

122861-53-4Doxycycline EP Impurity F

● Em Estoque

Nº do catálogo:	VL159002
Nº CAS:	122861-53-4
Fórmula Mol.::	C23H25NO8
Peso Mol.::	443.45 g/mol

Solicitar orçamento

Adicionar à lista de RFQ

Informações adicionais sobre o CAS 122861-53-4

Fármaco de origem

Doxycycline

Nome IUPAC

(4S,4aR,5S,5aR,6R,12aS)-2-acetyl-4-(dimethylamino)- 3,5,10,12,12a-pentahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,11(4H,5H)-dione

Sinônimos farmacopeicos

2-Acetyl 2-Decarbamoyl Doxycycline; Doxycycline Related Compound F

Outros sinônimos

1,11(4H,5H)-Naphthacenedione, 2-acetyl-4-(dimethylamino)-4a,5a,6,12a-tetrahydro-3,5,10,12,12a-pentahydroxy-6-methyl-, (4S,4aR,5S,5aR,6R,12aS)-

Smile

O=C1C(C(C)=O)=C(O)[C@@H](N(C)C)[C@@]2([H])[C@]1(O)C(O)=C(C(C3=C(O)C=CC=C3[C@@H]4C)=O)[C@]4([H])[C@@H]2O

InChI

InChI=1S/C23H25NO8/c1-8-10-6-5-7-11(26)14(10)18(27)15-12(8)19(28)16-17(24(3)4)20(29)13(9(2)25)21(30)23(16,32)22(15)31/h5-8,12,16-17,19,26-28,30,32H,1-4H3/t8-,12+,16+,17-,19-,23+/m0/s1

Condição de envio

Ambient Temperature

Characterization Data (Included)

HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, and Structure Elucidation Report (SER).

Dados adicionais de caracterização

QNMR, D2O Exchange, 13C NMR, 13C APT, COSY NMR, NOESY NMR, 15N NMR, HSQC NMR, HMQC NMR, and HMBC NMR. These are available upon request and may be free or subject to additional charges.

Descrição

Doxycycline EP Impurity F, also known in pharmacopoeias as 2-Acetyl 2-Decarbamoyl Doxycycline; Doxycycline Related Compound F, is a highly characterized reference material. It fully complies with stringent regulatory standards, including those set by USP, EMA, JP, and BP. This product is essential for use in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Doxycycline. Moreover, it comes with a detailed Structure Elucidation Report (SER), ensuring its accuracy and reliability for a wide range of analytical applications.

Referências

‘Smith, kelly, and James J. Leyden. “Safety of Doxycycline and Minocycline: A Systematic Review.” Clinical Therapeutics, vol. 27, no. 9, Sept. 2005, pp. 1329–42, https://doi.org/10.1016/j.clinthera.2005.09.005. ?Saivin, S., and G. Houin. “Clinical Pharmacokinetics of Doxycycline and Minocycline.” Clinical Pharmacokinetics, vol. 15, no. 6, Dec. 1988, pp. 355–66, https://doi.org/10.2165/00003088-198815060-00001 ‘